Literature DB >> 15100453

In vitro efficacy of antimalarial drugs against Plasmodium vivax on the western border of Thailand.

Kesinee Chotivanich1, Rachanee Udomsangpetch, Wirongrong Chierakul, Paul N Newton, Ronatrai Ruangveerayuth, Sasithon Pukrittayakamee, Sornchai Looareesuwan, Nicholas J White.   

Abstract

The susceptibility of 20 isolates of Plasmodium vivax on the Thailand-Myanmar border to seven antimalarial drugs was evaluated using the schizont maturation inhibition technique. The geometric mean 50% inhibition concentration (IC(50)) values were quinine = 308 ng/mL, amodiaquine =14 ng/mL, chloroquine =50 ng/mL, mefloquine = 127 ng/mL, sulfadoxine/pyrimethamine (80:1) = 800/10 ng/mL, pyrimethamine = 8 ng/mL, and artesunate = 0.5 ng/mL. Compared with P. falciparum in this area, P. vivax was more sensitive to chloroquine and artesunate, equally sensitive to quinine, and more resistant to mefloquine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15100453

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  22 in total

1.  The presence of leukocytes in ex vivo assays significantly increases the 50-percent inhibitory concentrations of artesunate and chloroquine against Plasmodium vivax and Plasmodium falciparum.

Authors:  S Kaewpongsri; K Sriprawat; R Suwanarusk; D E Kyle; U Lek-Uthai; M Leimanis; K M Lwin; A P Phyo; J Zwang; B Russell; F Nosten; L Renia
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

2.  In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.

Authors:  R N Price; J Marfurt; F Chalfein; E Kenangalem; K A Piera; E Tjitra; N M Anstey; B Russell
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

3.  In vitro anti-malarial drug susceptibility of temperate Plasmodium vivax from central China.

Authors:  Feng Lu; Qi Gao; Kesinee Chotivanich; Hui Xia; Jun Cao; Rachanee Udomsangpetch; Liwang Cui; Jetsumon Sattabongkot
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

4.  Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax.

Authors:  R Suwanarusk; M Chavchich; B Russell; A Jaidee; F Chalfein; M Barends; B Prasetyorini; E Kenangalem; K A Piera; U Lek-Uthai; N M Anstey; E Tjitra; F Nosten; Q Cheng; R N Price
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

Review 5.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

6.  In vitro susceptibility of Plasmodium vivax to antimalarials in Colombia.

Authors:  Diana Fernández; César Segura; Margarita Arboleda; Giovanny Garavito; Silvia Blair; Adriana Pabón
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

7.  Improved assessment of plasmodium vivax response to antimalarial drugs by a colorimetric double-site plasmodium lactate dehydrogenase antigen capture enzyme-linked immunosorbent assay.

Authors:  Pierre Druilhe; Philippe Brasseur; Catherine Blanc; Michael Makler
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

Review 8.  Vivax malaria: neglected and not benign.

Authors:  Ric N Price; Emiliana Tjitra; Carlos A Guerra; Shunmay Yeung; Nicholas J White; Nicholas M Anstey
Journal:  Am J Trop Med Hyg       Date:  2007-12       Impact factor: 2.345

Review 9.  Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax.

Authors:  Ric N Price; Sarah Auburn; Jutta Marfurt; Qin Cheng
Journal:  Trends Parasitol       Date:  2012-10-05

10.  Antimalarial drug susceptibility of Plasmodium vivax in the Republic of Korea.

Authors:  Kesinee Chotivanich; Jetsumon Sattabongkot; Yien Kyong Choi; Jae Sun Park; Juntima Sritabal; Chae Seung Lim; Rachanee Udomsangpetch; Nicholas J White; Won Ja Lee
Journal:  Am J Trop Med Hyg       Date:  2009-06       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.